Your gut has been running its own endocannabinoid system this entire time. Long before you heard of CBD, CB1 and CB2 receptors were distributed throughout your digestive tract from esophagus to colon, regulating how fast food moves through you, how much inflammation your gut tolerates, and how much pain it sends to your brain. Cannabinoids from hemp aren’t doing something foreign when they enter your GI system. They’re engaging a receptor network that was already there. CBG has the strongest gut-specific research of any cannabinoid, which is why it leads this article. CBD, THC, and CBN each have a supporting role. If you’re curious how THC itself is processed, see what happens to THC in your digestive system.
🧪 Lab Tested | 👩💼 Woman-Owned | 🏆 Est. 2017
The Endocannabinoid System in Your Gut
The ECS wasn’t discovered until the 1990s, which is part of why it doesn’t have the same textbook presence as the nervous or immune systems. That’s starting to change. A 2023 review by researchers at the Mayo Clinic, published in Clinical Gastroenterology and Hepatology (PMC10872845), confirmed that CB1 and CB2 receptors and their signaling pathways are present throughout the digestive system with well-documented roles in gut motility, immune response, visceral pain signaling, and intestinal barrier integrity.
CB1 receptors are densest in the enteric nervous system, sometimes called the “second brain,” which runs along the entire GI tract and handles most of the gut’s autonomous function. CB2 receptors are concentrated in the immune cells that line the gut wall. Phytocannabinoids interact with both. Different cannabinoids hit these receptors at different affinities and through different mechanisms, which is why CBG, CBD, and THC can all affect the gut while doing different things.
CBG: The Strongest Gut-Specific Evidence
CBG (cannabigerol) is the precursor from which most other cannabinoids are produced in the hemp plant, which is why researchers sometimes call it the “mother cannabinoid.” It’s present in smaller concentrations than CBD in most hemp flower, so it gets less attention.
The colitis model
A foundational study in Biochemical Pharmacology (PMID 23415610) found that CBG significantly reduced inflammation, oxidative stress, and intestinal damage in a mouse model of colitis. It reduced key inflammatory markers including iNOS expression and interleukin-1beta. The researchers concluded CBG should be considered for clinical experimentation in IBD patients. A 2024 follow-up in the Journal of Pharmacology and Experimental Therapeutics (JPET 2024) extended this finding: a high-CBG hemp extract dramatically reduced disease severity in mice with colitis and shifted their gut microbiome. In lab dishes, the extract also showed clade-specific antimicrobial activity against common human gut bacteria, which may help explain that shift.
The IBS clinical trial
In a 2023 proof-of-concept trial published in the American College of Gastroenterology journal (ACG 2023), adults with IBS took a CBD/CBG oral tincture to see whether it helped their symptoms. It’s an open-label conference abstract with no placebo group, so treat it as a first signal, not proof. Larger controlled studies are needed, but it’s human data on a CBD/CBG combination in an IBS population, which is rare.
How CBG works on gut tissue
In lab studies, CBG interacts with several receptor pathways in the gut: CB2 receptors in immune cells, TRPV1 channels tied to pain signaling, and 5-HT1A receptors linked to nausea and motility. Non-psychoactive at standard doses. If cramps are part of your gut picture, here’s our answer to does THC help with period cramps.
CBD and the Gut-Brain Axis
Most people reach for CBD for anxiety or sleep. The gut-brain axis is a two-way street, and CBD works both ends of it. Stress and gut disorders travel together so consistently that the mechanism isn’t coincidental: the vagus nerve directly connects the brain to the enteric nervous system, and the amygdala’s threat-response loop directly affects gut motility and secretion.
CBD’s gut-specific mechanisms go beyond the stress-gut connection. A 2024 review in the International Journal of Molecular Sciences (IJMS 2024) found that both THC and CBD may help restore normal intestinal permeability after disruption by influencing the synthesis of tight junction proteins, the molecular structures that hold the intestinal cell wall together. Disruption of these proteins is the mechanism underlying what’s commonly called “leaky gut.” The review points mainly to CB1 receptor signaling for that barrier effect.
Then there’s visceral pain, the deep, hard-to-describe gut discomfort that doesn’t always show up on a scan but can still derail your day. CBD’s activity at TRPV1, a pain-signaling channel, is one reason researchers are interested, but human trials on CBD for visceral pain are still thin.
THC and CBN: Supporting Roles
THC and motility
THC has the most extensive GI research of any cannabinoid, partly because it’s been studied longer and partly because its effects are unmistakable. The Mayo Clinic review noted that THC generally slows GI motility through CB1 receptor activation in the enteric nervous system. For conditions involving overactive motility (diarrhea-predominant IBS, urgency, cramping), slower transit is the therapeutic goal. THC also has well-established anti-nausea properties through CB1 receptors in the stomach, and it has been used medically in chemotherapy patients for decades on that basis. CB1 activation reduces gastric acid secretion and has protective effects on the gastric lining.
The psychoactive effect limits THC’s daytime utility for most users. Delta 9 THC gummies in a low-dose formula (the approach in our Smooth Operator gummies, with 10mg each of THC, CBD and CBG) are a more controlled entry point than higher-potency formats. Delta 9 THC products will produce a positive result on standard drug tests.
CBN and the NREM-gut repair cycle
CBN (cannabinol) is best known as a sleep cannabinoid, and sleep and gut health are tied together. Your body does a lot of its repair work during deep sleep, and poor sleep and gut trouble tend to travel together.
There’s very little direct research on CBN and the gut, so its role here is indirect: if it helps you sleep better, your gut gets more of the overnight recovery it needs.
Why Full-Spectrum Coverage Matters
Cannabinoids don’t work in isolation in the gut any more than they do in other systems. A 2023 mini-review in Medical Cannabis and Cannabinoids (Turco et al. 2023) describes the ECS as tied into both the gut microbiome and the gut-brain axis, with the microbiome and ECS tone shaping each other in both directions. Several receptor types are in play in the gut, including CB1, CB2, TRPV1, GPR55 and PPARalpha.
Beta-caryophyllene, a terpene present in full-spectrum hemp, is also a CB2 agonist. It adds another anti-inflammatory layer at the gut’s immune cell receptors independent of the cannabinoid content. Full-spectrum formulations get you this kind of coverage by default; isolates don’t.
Cannabinoid Gut-Health Comparison
| Cannabinoid | Primary Gut Mechanism | Strongest Evidence | Drug Test Risk |
| CBG | CB2 anti-inflammatory, TRPV1 pain modulation, microbiome modulation | Colitis animal models, IBS proof-of-concept trial (ACG 2023) | Low but real (full-spectrum trace D9) |
| CBD | TRPV1 visceral pain, tight junction protein support, gut-brain axis via 5-HT1A | Intestinal permeability (IJMS 2024) | Low but real (full-spectrum trace D9) |
| THC (Delta 9) | CB1 motility reduction, anti-nausea, gastric acid reduction | Motility and nausea (established; Mayo Clinic review 2023) | Will produce a positive drug test |
| CBN | Indirect: sleep support | Little direct gut data | Low but real (full-spectrum trace D9) |
TribeTokes Products for Gut Health
Lead Cannabinoid for Gut: CB2, TRPV1, 5-HT1A
CBG Tincture (Full Spectrum)
★★★★★ 4.88 from 17 reviews
CBG + CBD
Full Spectrum
Sublingual
Non-Psychoactive
CBG is the lead gut-health cannabinoid in the research. In lab studies, CBG works on the same CB2, TRPV1 and 5-HT1A pathways covered above, and a sublingual tincture is an easy way to take it every day. It pairs CBG with CBD, the same two cannabinoids tested in the 2023 ACG IBS proof-of-concept trial. Full-spectrum trace D9: low but real drug test risk; review COA at tribetokes.com/certificates-of-analysis. “One of the TT owners suggested this tincture for my IBS symptoms. I’ve been using it for about three weeks now and it seems to be making a big difference,” Amey S.
CBD + CBG: Visceral Pain and Gut-Brain Axis
CBD Live Resin Gummies (CBG-Boosted)
★★★★★ 4.92 from 36 reviews
Full Spectrum CBD
CBG-Boosted
Live Resin
Vegan
Full-spectrum CBD with CBG boost for daily gut-brain axis support and visceral pain management. Oral consumption delivers cannabinoids through the GI tract directly, which may increase local bioavailability at the gut wall compared to inhalation routes. The live resin extraction preserves the full terpene and minor cannabinoid profile, including beta-caryophyllene’s additional CB2 activity. Non-psychoactive. Full-spectrum trace D9: low but real drug test risk; review COA at tribetokes.com/certificates-of-analysis.
THC: Motility, Nausea, Overactive GI Symptoms
Smooth Operator THC + CBD + CBG Gummies
★★★★★ 4.93 from 41 reviews
Delta 9 THC
CBD-Boosted
Vegan
Positive Drug Test
For overactive GI symptoms where slowing motility is the goal: diarrhea-predominant IBS, urgency, cramping, nausea. THC’s CB1-mediated motility reduction is one of the most established mechanisms in GI cannabinoid research. Start with a partial gummy and assess the full 45 to 90 minute window before a second dose. Psychoactive at standard doses. Will produce a positive result on standard drug tests. Review COA at tribetokes.com/certificates-of-analysis.
Frequently Asked Questions
Early research suggests yes, particularly for pain and symptom management. A small 2023 open-label trial in the ACG journal tested a CBD/CBG oral tincture in adults with IBS. It had no placebo group, so it’s a first look, not proof. The lab research points the same way: both cannabinoids interact with CB1, CB2, and TRPV1 receptors involved in gut pain, motility, and inflammation. Larger controlled trials are still needed before clinical recommendations can be made.
CBG has the most direct gut-inflammation research. In mice with colitis, it reduced key inflammatory markers in colonic tissue, including iNOS and interleukin-1beta, and a 2024 mouse study found a high-CBG hemp extract also shifted the gut microbiome. CBD has meaningful anti-inflammatory data as well, particularly for intestinal permeability. Both cannabinoids work through different receptor pathways; full-spectrum or CBG-boosted formulas cover more of the gut’s inflammatory biology than either alone.
THC has well-established effects on two specific GI problems: it slows motility through CB1 receptor activation (useful for diarrhea-predominant IBS, urgency, and cramping) and reduces nausea through the same mechanism (used medically in chemotherapy patients for decades). It also reduces gastric acid secretion and has protective effects on the gastric lining. For constipation-predominant IBS or conditions where slower motility would make symptoms worse, THC is not the right tool. Delta 9 THC products will produce a positive result on standard drug tests.
The ECS regulates four key functions throughout the GI tract: intestinal motility (how fast food moves), gut barrier integrity (the tightness of the intestinal wall), immune response (inflammation levels in the gut lining), and visceral pain signaling (how much gut discomfort reaches the brain). CB1 receptors are concentrated in the enteric nervous system; CB2 receptors are concentrated in gut immune cells.
Yes. The 2023 ACG IBS trial specifically tested a combined CBD/CBG oral tincture. The two cannabinoids work through overlapping but distinct receptor pathways: CBD through TRPV1 and 5-HT1A primarily; CBG through CB2, TRPV1, and 5-HT1A. A CBG-boosted CBD product covers more of the gut’s receptor landscape than either cannabinoid in isolation.
Oral consumption delivers cannabinoids through the GI tract, which may increase local bioavailability at the gut wall compared to inhalation. Sublingual tincture tends to kick in faster than a gummy and also delivers cannabinoids through oral mucosa before they enter the GI tract proper. For gut-specific applications, both formats are reasonable choices. Formulation matters too. Full-spectrum formulations without artificial ingredients preserve the complete cannabinoid and terpene profile.
Our full-spectrum CBD and CBG products contain trace amounts of Delta 9 THC. Full-spectrum CBD and CBG carry low but real drug test risk with regular daily ingested use. Delta 9 THC gummies will produce a positive result on standard drug tests. Anyone subject to drug testing should review COA levels at tribetokes.com/certificates-of-analysis before choosing a product.
The gut ECS engages at multiple receptor types simultaneously: CB1, CB2, TRPV1, GPR55, and PPARalpha. No single cannabinoid activates all of them. Full-spectrum formulations preserve the complete cannabinoid and terpene profile, including beta-caryophyllene, a terpene that acts as a CB2 agonist and adds anti-inflammatory activity at the gut’s immune receptors. A 2023 paper in Medical Cannabis and Cannabinoids specifically noted that the ECS-gut axis involves multiple receptor types and that multi-cannabinoid preparations may cover that complexity better than isolates do.
Your Gut’s Endocannabinoid System Is Already There.
CBG leads. Full-spectrum covers. Lab-tested, COA on every batch. Woman-owned since 2017.
